Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin

NCT00012324 is registered in ClinicalTrials.gov with Eximias Pharmaceutical as lead sponsor.

NCT NCT00012324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00012324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin
Lead sponsor
Eximias Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2000
Completion date
November 30, 2005
Enrollment
Not reported
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer